Arabic Arabic English English French French German German
dark

Impel NeuroPharma Launches Reroute Migraine Relief

Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief , an educational initiative which aims to raise awareness of the complexities of migraine, including the underrecognized connection between the brain and gut. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

OAG report into vaccine programme ‘useful and timely’ says Ministry

Next Post

Kelyniam Global Releases Q1 Financial Results – Profitability Despite the 2nd Wave Pandemic

Related Posts
Total
0
Share